Cargando…

Binding kinetics of cariprazine and aripiprazole at the dopamine D(3) receptor

The dissociation behaviours of aripiprazole and cariprazine at the human D(2) and D(3) receptor are evaluated. A potential correlation between kinetics and in vivo profiles, especially cariprazine’s action on negative symptoms in schizophrenia, is investigated. The binding kinetics of four ligands w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Frank, Annika, Kiss, Dóra J., Keserű, György M., Stark, Holger
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104066/ https://www.ncbi.nlm.nih.gov/pubmed/30131592 http://dx.doi.org/10.1038/s41598-018-30794-y

Ejemplares similares

Cariprazine Exhibits Anxiolytic and Dopamine D(3) Receptor-Dependent Antidepressant Effects in the Chronic Stress Model
por: Duric, Vanja, et al.
Publicado: (2017)

Cariprazine exerts antimanic properties and interferes with dopamine D(2) receptor β-arrestin interactions
por: Gao, Yonglin, et al.
Publicado: (2015)

Preferential binding to dopamine D(3) over D(2) receptors by cariprazine in patients with schizophrenia using PET with the D(3)/D(2) receptor ligand [(11)C]-(+)-PHNO
por: Girgis, Ragy R., et al.
Publicado: (2016)

The novel atypical antipsychotic cariprazine demonstrates dopamine D(2) receptor‐dependent partial agonist actions on rat mesencephalic dopamine neuronal activity
por: Delcourte, Sarah, et al.
Publicado: (2018)

The Effects of Cariprazine and Aripiprazole on PCP-Induced Deficits on Attention Assessed in the 5-Choice Serial Reaction Time Task
por: Barnes, Samuel A., et al.
Publicado: (2018)

Correction to: The Effects of Cariprazine and Aripiprazole on PCP-Induced Deficits on Attention Assessed in the 5-Choice Serial Reaction Time Task
por: Barnes, Samuel A., et al.
Publicado: (2018)

The antipsychotic medications aripiprazole, brexpiprazole and cariprazine are off-target respiratory chain complex I inhibitors
por: Hardy, Rachel E., et al.
Publicado: (2023)

PharmacoSTORM nanoscale pharmacology reveals cariprazine binding on Islands of Calleja granule cells
por: Prokop, Susanne, et al.
Publicado: (2021)

The Impact of the Secondary Binding Pocket on the Pharmacology of Class A GPCRs
por: Egyed, Attila, et al.
Publicado: (2022)

Cariprazine, A Dopamine D(2)/D(3) Receptor Partial Agonist, Modulates ABCG2-Mediated Multidrug Resistance in Cancer
por: Hussein, Noor, et al.
Publicado: (2018)

Preferential Effects of Cariprazine on Counteracting the Disruption of Social Interaction and Decrease in Extracellular Dopamine Levels Induced by the Dopamine D(3) Receptor Agonist, PD-128907 in Rats: Implications for the Treatment of Negative and Depressive Symptoms of Psychiatric Disorders
por: Kehr, Jan, et al.
Publicado: (2022)

Dopamine receptor D(2) activation suppresses the radiosensitizing effect of aripiprazole via activation of AMPK
por: Lee, Hyounji, et al.
Publicado: (2019)

Discovery research and development history of the dopamine D(2) receptor partial agonists, aripiprazole and brexpiprazole
por: Kikuchi, Tetsuro, et al.
Publicado: (2021)

Effects of Cariprazine, Aripiprazole, and Olanzapine on Mouse Fibroblast Culture: Changes in Adiponectin Contents in Supernatants, Triglyceride Accumulation, and Peroxisome Proliferator-Activated Receptor-γ Expression
por: Bába, László-István, et al.
Publicado: (2019)

Cariprazine pharmacokinetics
Publicado: (2022)

Treatment of Symptom Clusters in Schizophrenia, Bipolar Disorder and Major Depressive Disorder With the Dopamine D3/D2 Preferring Partial Agonist Cariprazine
por: Batinic, Borjanka, et al.
Publicado: (2021)

Cariprazine hydrochloride for schizophrenia
Publicado: (2021)

Cariprazine in the treatment of schizophrenia: a proof-of-concept trial
por: Durgam, Suresh, et al.
Publicado: (2016)

The Multi-Targeting Ligand ST-2223 with Histamine H(3) Receptor and Dopamine D(2)/D(3) Receptor Antagonist Properties Mitigates Autism-Like Repetitive Behaviors and Brain Oxidative Stress in Mice
por: Eissa, Nermin, et al.
Publicado: (2021)

Dopamine D(2) Receptor Agonist Binding Kinetics—Role of a Conserved Serine Residue
por: Ågren, Richard, et al.
Publicado: (2021)

Neuronal Dopamine D3 Receptors: Translational Implications for Preclinical Research and CNS Disorders
por: Kiss, Béla, et al.
Publicado: (2021)

Dopamine D3 Receptor Antagonists as Potential Therapeutics for the Treatment of Neurological Diseases
por: Maramai, Samuele, et al.
Publicado: (2016)

Preclinical pharmacodynamic and pharmacokinetic characterization of the major metabolites of cariprazine
por: Kiss, Béla, et al.
Publicado: (2019)

Dopamine Synthesis Capacity is Associated with D2/3 Receptor Binding but Not Dopamine Release
por: Berry, Anne S, et al.
Publicado: (2018)

Effects of Dopamine D(2) Receptor Partial Agonist Antipsychotic Aripiprazole on Dopamine Synthesis in Human Brain Measured by PET with L-[β-(11)C]DOPA
por: Ito, Hiroshi, et al.
Publicado: (2012)

Synthesis and In Vitro Evaluation of Novel Dopamine Receptor D(2) 3,4-dihydroquinolin-2(1H)-one Derivatives Related to Aripiprazole
por: Juza, Radomir, et al.
Publicado: (2021)

Clinical effects of Cariprazine and their relationship with polymorphisms of dopamine and serotonin receptors: preliminary results from a prospective study on schizophrenia and bipolar disorder
por: De Pieri, M., et al.
Publicado: (2022)

Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism
por: de Bartolomeis, Andrea, et al.
Publicado: (2015)

Cariprazine Safety in Adolescents and the Elderly: Analyses of Clinical Study Data
por: Szatmári, Balázs, et al.
Publicado: (2020)

Agonist and Antagonist Effects of Aripiprazole on D(2)-Like Receptors Controlling Rat Brain Dopamine Synthesis Depend on the Dopaminergic Tone
por: Ma, Guo Fen, et al.
Publicado: (2015)

The improvement of motor symptoms in Huntington’s disease during cariprazine treatment
por: Csehi, Reka, et al.
Publicado: (2023)

Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety
por: Laszlovszky, István, et al.
Publicado: (2021)

Functional single nucleotide polymorphisms in dopaminergic receptors D2 predict clinical response to Cariprazine
por: De Pieri, Marco, et al.
Publicado: (2023)

Synthesis, Molecular Properties Estimations, and Dual Dopamine D(2) and D(3) Receptor Activities of Benzothiazole-Based Ligands
por: Schübler, Moritz, et al.
Publicado: (2017)

Influence of CYP2D6 Phenotypes on the Pharmacokinetics of Aripiprazole and Dehydro-Aripiprazole Using a Physiologically Based Pharmacokinetic Approach
por: Kneller, Lisa Alina, et al.
Publicado: (2021)

The novel antipsychotic cariprazine stabilizes gamma oscillations in rat hippocampal slices
por: Meier, Maria A., et al.
Publicado: (2020)

Place of the partial dopamine receptor agonist aripiprazole in the management of schizophrenia in adults: a Delphi consensus study
por: Llorca, Pierre-Michel, et al.
Publicado: (2022)

Dopamine supersensitivity psychosis and dopamine partial agonist: A retrospective survey of failure of switching to aripiprazole in schizophrenia
por: Takase, Masayuki, et al.
Publicado: (2015)

Cariprazine: Patients with Treatment-Resistant Schizophrenia
por: Aubel, Thomas
Publicado: (2021)

Defining the therapeutic reference range for cariprazine
por: Kapás, M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_s7954hn2c6idltk4391pu5mr5o